Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib

Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Englinger, Bernhard, Laemmerer, Anna, Moser, Patrick, Kallus, Sebastian, Röhrl, Clemens, Pirker, Christine, Baier, Dina, Mohr, Thomas, Niederstaetter, Laura, Meier‐Menches, Samuel M., Gerner, Christopher, Gabler, Lisa, Gojo, Johannes, Timelthaler, Gerald, Senkiv, Julia, Jäger, Walter, Kowol, Christian R., Heffeter, Petra, Berger, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497038/
https://www.ncbi.nlm.nih.gov/pubmed/32064608
http://dx.doi.org/10.1002/ijc.32924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497038/
https://www.ncbi.nlm.nih.gov/pubmed/32064608
http://dx.doi.org/10.1002/ijc.32924

Ejemplares similares